July 2, 2009
FDA approves new fibrillation drug
The U.S. Food and Drug Administration announced approval Thursday of Multaq tablets to help maintain normal heart rhythms in patients with heart disorders.
The FDA said Multaq (dronedarone) is designed to treat atrial fibrillation or atrial flutter in patients whose hearts have returned to normal rhythm or who will undergo drug or electric-shock treatment to restore a normal heart beat.
Multaq is manufactured by the French pharmaceutical company Sanofi-Aventis.